# A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions

> **NCT03876106** · PHASE1 · COMPLETED · sponsor: **Lutris Pharma Ltd.** · enrollment: 10 (actual)

## Conditions studied

- EGFR Inhibitor Induced Acneiform Lesions

## Interventions

- **DRUG:** LUT014

## Key facts

- **NCT ID:** NCT03876106
- **Lead sponsor:** Lutris Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-21
- **Primary completion:** 2020-07-09
- **Final completion:** 2020-11-18
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03876106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03876106, "A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03876106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*